<DOC>
	<DOCNO>NCT00106145</DOCNO>
	<brief_summary>An investigational study determine safety/tolerability , efficacy notch signal pathway inhibitor patient metastatic locally advanced breast cancer advance solid tumor .</brief_summary>
	<brief_title>A Notch Signalling Pathway Inhibitor Patients With Advanced Breast Cancer ( 0752-014 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women men great equal 18 year age ECOG status less equal 2 ( measurement determine ability perform daily activity ) In Parts I , III , IV , patient must histologically confirm , metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist . There limit number prior treatment regimen In Part II , breast cancer patient eligible In Part V , patient Numb negative breast cancer ( i.e. , tumor show Numb immunoreactivity le 10 % neoplastic cell assess ) eligible Patient recover least 2 week previous antineoplastic therapy , include chemotherapy , biological therapy ( include Herceptin ) , hormonal therapy , radiotherapy , surgery Patient investigational treatment precede 21 day Uncontrolled congestive heart failure myocardial infarction ( heart attack ) within 3 month study start History hepatitis B C HIV Patient presence clinically apparent central nervous system metastases carcinomatous meningitis . Patients CNS metastasis complete course radiotherapy clinically stable judgment investigator eligible Patients `` currently active '' second malignancy , nonmelanoma skin cancer , enrol . Patients consider `` currently active '' malignancy complete therapy prior malignancy consider physician &lt; 30 % risk relapse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>